Role of Obesity Management in Cardiovascular Disease Prevention, with Diana Isaacs, PharmD

Published on: 

The scope of use for pharmacologic agents traditionally used in management have diabetes have undergone a monumental change in recent years.

As a result of trials examining long-term cardiovascular safety of antihyperglycemic agents, revelations related to the cardiovascular benefits of GLP-1 receptor agonists and SGLT2 inhibitors transformed their role in management of diabetes. And, although SGLT2 inhibitors have sown proven cardiorenal protective benefits in people without diabetes in phase 3 clinical trials, the effects of GLP-1 receptor agonists could soon play a major role in prevention of cardiovascular disease on a population level.

Despite advances in pharmacology, knowledge, and technologies, the ballooning obesity and overweight epidemic have caused progress against many chronic conditions to slow or have reversed trends entirely. With emerging data outlining the role of semaglutide 2.4 in populations with increased body weight, many in public health are hopeful optimized uptake could have a historic impact.

Following a panel discussion on application of cardiometabolic health guidelines from various organizations to real-world patient populations at the American Heart Association 2022 Scientific Sessions, Diana Isaacs, PharmD, an endocrine clinical pharmacist and CGM program coordinator at the Cleveland, sat down with our editorial team to provide perspective on the role of antihyperglycemic agents in cardiovascular risk reduction and the potential of these agents for attenuating risk on a population level

For more insights on management of diabetes with Diana Isaacs, PharmD, check out her podcast Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives.